ライフサイエンスコーパス: daytime sleepiness

1 time sleepiness) to 24 points (high level of daytime sleepiness).

2 nge from 0-24, with values <10 suggesting no daytime sleepiness).

3 ry disease (CAD), many of whom do not report daytime sleepiness.

4 and covariation of obesity with snoring and daytime sleepiness.

5 s and one important outcome, the severity of daytime sleepiness.

6 eep are a well recognized cause of excessive daytime sleepiness.

7 arding the relationship between mild OSA and daytime sleepiness.

8 quantity, poor sleep quality, and excessive daytime sleepiness.

9 lt in transient but substantial increases in daytime sleepiness.

10 nsomnia, delayed sleep habits, and excessive daytime sleepiness.

11 a sleep study for patients with unexplained daytime sleepiness.

12 ) display significant sleep disturbances and daytime sleepiness.

13 p apnea is a common disease, responsible for daytime sleepiness.

14 a nearly significant decrease in subjective daytime sleepiness.

15 ude hypothalamic injury, with inactivity and daytime sleepiness.

16 out (n=144) complaints of frequent excessive daytime sleepiness.

17 ict important consequences such as excessive daytime sleepiness.

18 ould prove useful in prediction of excessive daytime sleepiness.

19 may reduce sleep fragmentation and excessive daytime sleepiness.

20 idence interval): 2.97 (2.65-3.34)), regular daytime sleepiness (2.66 (2.34-3.01)), and regular insom

21 n 0.53 and 1.33; P < 0.001 for all domains), daytime sleepiness (-2.92; P < 0.001), mood state (-4.24

22 owed high risk for OSAS, 46.3% had excessive daytime sleepiness, 41.5% were positive for both the Bq

23 Excessive daytime sleepiness affected 32% of the patients, sometim

24 eads to annoyance, disturbs sleep and causes daytime sleepiness, affects patient outcomes and staff p

25 urologic disorder characterized by excessive daytime sleepiness and abnormal manifestations of REM sl

26 t (REM) sleep, is characterized by excessive daytime sleepiness and cataplexy, a loss of muscle tone

27 an sleep disorder characterized by excessive daytime sleepiness and cataplexy.

28 litating disorder characterized by excessive daytime sleepiness and cataplexy.

29 colepsy, which is characterized by excessive daytime sleepiness and cataplexy.

30 were significantly more likely to experience daytime sleepiness and dozing during daytime activities.

31 isordered breathing (SDB) is associated with daytime sleepiness and impaired quality of life.

32 Therapeutic NCPAP reduces excessive daytime sleepiness and improves self-reported health sta

33 )) and between increased levels of excessive daytime sleepiness and increased measures for adiposity

34 roducing, respectively, narcolepsy excessive daytime sleepiness and poor sleep quality.

35 efits, and substantially improving excessive daytime sleepiness and quality of life.

36 th Sleepiness Scale (ESS) was used to assess daytime sleepiness and standardized questionnaires asses

37 dy aimed to explore the relationship between daytime sleepiness and the risk of ischemic stroke and v

38 Daytime sleepiness and time to fall asleep decreased dur

39 ance syndrome (UARS) is defined by excessive daytime sleepiness and tiredness, and is associated with

40 he basis of characteristic history (snoring, daytime sleepiness) and physical examination (increased

41 variance in obesity, 40% of the variance in daytime sleepiness, and 23% of the variability in self-r

42 e evaluated sleep characteristics, excessive daytime sleepiness, and chronotype using the Pittsburgh

43 with self-reported parental sleep duration, daytime sleepiness, and dozing among employed adults.

44 leep restriction, irregular sleep schedules, daytime sleepiness, and elevated risk for sleep disturba

45 reasoning, as well as insomnia, depression, daytime sleepiness, and headaches), 2 ("confusion-ataxia

46 and patient-reported measures of depression, daytime sleepiness, and quality of life.

47 ale score, the visual analog scale score for daytime sleepiness, and sleep log-derived and actigraphy

48 ring sleep are not associated with excessive daytime sleepiness, and therefore appear unlikely to con

49 ence increased nocturnal activity, excessive daytime sleepiness, and weight loss.

50 of the clinical features (i.e., significant daytime sleepiness, anxiety and depression symptoms, pot

51 and fatigue (aOR, 1.59; 95% CI, 1.16-2.19), daytime sleepiness (aOR, 1.81; 95% CI, 1.28-2.55), or in

52 r data show that: (1) poor sleep quality and daytime sleepiness are problems common to all types of I

53 Self-reported daytime sleepiness associated with increased risk for al

54 ervous system disorders, including excessive daytime sleepiness, attention deficit hyperactivity diso

55 This study supports the notion that daytime sleepiness, but not nighttime sleeping duration,

56 Excessive daytime sleepiness can be evaluated with both subjective

57 a sleep disorder characterized by excessive daytime sleepiness, cataplexy, and other pathological ma

58 It is characterized by daytime sleepiness, cataplexy, and striking transitions

59 ological disorder characterized by excessive daytime sleepiness, cataplexy, hypnagonic hallucinations

60 The complaint of excessive daytime sleepiness, commonly encountered in neurological

61 state, anxiety and depressive symptoms, and daytime sleepiness compared with conservative treatment.

62 r nocturnal-assist servoventilation improves daytime sleepiness compared with the control.

63 The prevalence of excessive daytime sleepiness, defined as an ESS score >/= 11, incr

64 ea/hypopnea syndrome can experience residual daytime sleepiness despite regular use of nasal continuo

65 Perceived sleep quality and daytime sleepiness did not change over the course of the

66 polysomnography with complaints of excessive daytime sleepiness (EDS) and clinically suspected obstru

67 ted by exploring the links between excessive daytime sleepiness (EDS) and vulnerability to infectious

68 the treatment of disorders such as excessive daytime sleepiness (EDS) as well as other sleep or cogni

69 e the safety and efficacy of LT on excessive daytime sleepiness (EDS) associated with PD.

70 We assessed whether excessive daytime sleepiness (EDS) at baseline was associated with

71 Excessive daytime sleepiness (EDS) is common and disabling in Park

72 nd snoring and between obesity and excessive daytime sleepiness (EDS), although for the most part the

73 The percentage of patients with normalized daytime sleepiness (Epworth score < 10) was significantl

74 (Pittsburgh Sleep Quality Index [PSQI]) and daytime sleepiness (Epworth Sleepiness Scale [ESS]).

75 daytime sleepiness, patients with excessive daytime sleepiness (Epworth Sleepiness Scale score >/=10

76 Patients with self-reported daytime sleepiness (Epworth Sleepiness Scale score >10)

77 d OSA (apnea-hypopnea index >/=15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10)

78 quality (Pittsburgh Sleep Quality Index) and daytime sleepiness (Epworth Sleepiness Scale), and circa

79 ere habitual snorers, 18% reported excessive daytime sleepiness (ESS > or = 11), and 29% were obese (

80 der narcolepsy is characterized by excessive daytime sleepiness, fragmentation of nighttime sleep, an

81 Excessive daytime sleepiness has emerged as one of the most common

82 normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.

83 fect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.

84 distinct differential diagnosis of excessive daytime sleepiness in older adults.

85 a that self-reported symptoms of snoring and daytime sleepiness in older men have a genetic basis tha

86 ssessing multiple risk factors for excessive daytime sleepiness in older subjects (mean age, 78 years

87 ilation produces an improvement in excessive daytime sleepiness in patients with Cheyne-Stokes breath

88 nct treatment for the management of residual daytime sleepiness in patients with obstructive sleep ap

89 gmentation (SF) appear to underlie excessive daytime sleepiness in patients with sleep apnea (OSA).

90 The etiology of excessive daytime sleepiness in patients with sleep-disordered bre

91 y of modafinil for the treatment of residual daytime sleepiness in such patients.

92 ep duration, insomnia symptoms and excessive daytime sleepiness in the UK Biobank (n = 112,586).

93 ommon medical disorder that causes excessive daytime sleepiness, increasing the risk for drowsy drivi

94 ma associated with atopy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of

95 re seen by neurologists, including excessive daytime sleepiness, insomnia, narcolepsy, rapid eye move

96 Daytime sleepiness is an independent risk factor for str

97 Excessive daytime sleepiness is typically the most frequent compla

98 re (CPAP), but its value in patients without daytime sleepiness is uncertain.

99 Preliminary evidence suggests that daytime sleepiness may predate clinical diagnosis of Par

100 [SE] difference, -0.42 [0.09], P < .001) and daytime sleepiness (mean [SE] difference, -0.24 [0.09],

101 Secondary endpoints included changes in daytime sleepiness, mood state, anxiety, and depression.

102 ypertension, cardiovascular disease, stroke, daytime sleepiness, motor vehicle accidents, and diminis

103 BI in females and WDR27 in males), excessive daytime sleepiness (near AR-OPHN1) and a composite sleep

104 11-2.10) (P = .009, I2 = 74%), and excessive daytime sleepiness (OR, 2.27; 95% CI, 1.54-3.35) (P < .0

105 ted OR, 2.65; P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and those with >

106 14-1.88) (P = .003, I2 = 76%), and excessive daytime sleepiness (OR, 2.72; 95% CI, 1.32-5.61) (P = .0

107 es such that eczema associated with fatigue, daytime sleepiness, or insomnia was associated with even

108 ilability and fatigue, depression, excessive daytime sleepiness, or rapid eye movement sleep behaviou

109 menopausal women with complaints of snoring, daytime sleepiness, or unsatisfactory sleep.

110 Daytime sleepiness (Osler test) was measured before and

111 igraphy measured duration and fragmentation, daytime sleepiness, overall quality, self-reported durat

112 Compared with PD patients without excessive daytime sleepiness, patients with excessive daytime slee

113 quantity, poor sleep quality, and excessive daytime sleepiness, studied according to an a priori pro

114 onclude that within a group of patients with daytime sleepiness, suspected OSA, and a normal RDI, the

115 In patients with OSA without daytime sleepiness, the prescription of CPAP compared wi

116 Active treatment reduced excessive daytime sleepiness; the mean Osler change was +7.9 minut

117 t, and carefully monitor changes in mood and daytime sleepiness throughout the intervention.

118 s Scale (ESS) score, which ranges from 0 (no daytime sleepiness) to 24 points (high level of daytime

119 phalopathy might be unable, due to excessive daytime sleepiness, to accumulate the need/ability to pr

120 4.9 + 3.2, chronotype was 63.6 +/- 10.8 and daytime sleepiness was 7.4 +/- 4.8.

121 Daytime sleepiness was also associated with NC (P = 0.02

122 The prevalence of insomnia and daytime sleepiness was not significantly higher compared

123 Daytime sleepiness was trichotomized using previously re

124 abnormal rapid eye movement (REM) sleep and daytime sleepiness, was examined using the canine model.

125 treatment) and OSA concomitant with habitual daytime sleepiness were estimated using repeated-measure

126 This condition causes recurrent insomnia and daytime sleepiness when the rhythms drift out of phase w

127 Modafinil significantly improved daytime sleepiness, with significantly greater mean chan

128 nea or >/= 2 hallmarks of OSA: loud snoring, daytime sleepiness, witnessed apnea, and hypertension.